Drug Type Small molecule drug |
Synonyms QR 12000, QR12000 |
Target |
Action antagonists, inhibitors |
Mechanism AT2R antagonists(Angiotensin II receptor type 2 antagonists), enkephalinase inhibitors(Neprilysin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Phase 3 | China | 22 Oct 2025 | |
| Essential Hypertension | Phase 3 | China | 16 Dec 2024 | |
| Heart Failure | Phase 2 | China | - |





